CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TheraBiogen, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TheraBiogen, Inc.
120 Wall St
Suite 2401
Phone: (866) 284-9561p:866 284-9561 New York, NY  10005  United States
On 11/5/2012, the Company announced that its principal lender, which holds a first priority security interest in its assets, has declared the Company in default of its obligations. Unless foreclosure and sale is postponed or alternative arrangements can be made, the Company will be without any operating assets as a result, and will no longer be able to engage in any business activity or pay its debts. While the Board of Directors has discussed the possibility of filing a Chapter 11 bankruptcy proceeding, a lack of any cash or other resources needed to retain a bankruptcy attorney to commence and maintain such an action has precluded this option.
On 11/9/2012, the Company was advised that a creditor of the Company has completed its foreclosure of the Company’s assets, including the license to manufacture, market, and sell the TheraMax™ homeopathic cold and flu products which have been distributed by the Company.
This company is no longer actively traded on any major stock exchange.
Business Summary
TheraBiogen, Inc. (TheraBiogen) is a developer and manufacturer of over-the-counter homeopathic pharmaceutical products which aid in the relief of various symptoms and illnesses. The Company develops and markets homeopathic over-the-counter pharmaceutical products to consumers in the United States, through retail pharmaceutical outlets. The development and marketing of homeopathic nasal spray products is its primary business. The Company’s nasal products include THERA MAX Cold and Flu relief, THERA MAX Allergy Relief and THERA MAX Migraine Relief. The Company has also developed THERA MAX Sore Throat Relief nasal product. The Company's homeopathic nasal spray products are cold and flu remedies product. They are all natural, homeopathic and delivered nasally to interact with the immune system so that the immune system can then deal with the symptoms and the illness itself.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
5/31/20122/29/2012YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
1000 Metal mining

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Compliance Officer, Secretary Phillip D.Forman 5/22/2012 3/10/2011
Director PasqualePetruzzo 54 5/22/2012 5/22/2012

Business Names
Business Name
Kushi Resources Inc
Kushi Resources Inc(NDA)
TERRA TREMA INC
5 additional Business Names available in full report.

General Information
Number of Employees: 4 (As of 2/29/2012)
Outstanding Shares: 71,392,815 (As of 5/31/2012)
Shareholders: 170
Stock Exchange: OTC
Federal Tax Id: 980559606


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023